RAPT vs. NKTR, HOWL, AKBA, VTYX, INZY, VNDA, NBTX, XERS, PYXS, and VSTM
Should you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Nektar Therapeutics (NKTR), Werewolf Therapeutics (HOWL), Akebia Therapeutics (AKBA), Ventyx Biosciences (VTYX), Inozyme Pharma (INZY), Vanda Pharmaceuticals (VNDA), Nanobiotix (NBTX), Xeris Biopharma (XERS), Pyxis Oncology (PYXS), and Verastem (VSTM). These companies are all part of the "pharmaceutical preparations" industry.
Nektar Therapeutics (NASDAQ:NKTR) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, community ranking, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 3.1% of Nektar Therapeutics shares are owned by insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Nektar Therapeutics received 539 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 70.61% of users gave Nektar Therapeutics an outperform vote while only 67.69% of users gave RAPT Therapeutics an outperform vote.
In the previous week, Nektar Therapeutics had 3 more articles in the media than RAPT Therapeutics. MarketBeat recorded 3 mentions for Nektar Therapeutics and 0 mentions for RAPT Therapeutics. RAPT Therapeutics' average media sentiment score of 0.00 equaled Nektar Therapeutics'average media sentiment score.
Nektar Therapeutics presently has a consensus price target of $3.50, suggesting a potential upside of 125.65%. RAPT Therapeutics has a consensus price target of $25.67, suggesting a potential upside of 218.44%. Given Nektar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe RAPT Therapeutics is more favorable than Nektar Therapeutics.
RAPT Therapeutics has lower revenue, but higher earnings than Nektar Therapeutics. RAPT Therapeutics is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.
RAPT Therapeutics has a net margin of 0.00% compared to RAPT Therapeutics' net margin of -306.31%. Nektar Therapeutics' return on equity of -63.14% beat RAPT Therapeutics' return on equity.
Nektar Therapeutics has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500.
Summary
RAPT Therapeutics beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.
Get RAPT Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RAPT Therapeutics Competitors List
Related Companies and Tools
